NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ANNX

Annexon Inc

Jul 14 • 04:00PM ET

2.61

Dollar change +0.03
Percentage change 1.16	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX RARE CRSP NTLA EDIT ALLO BLUE FOLD MYO SGMO

| Held by: IWM VTI VXF IWN IBB SCHA VTWO DFAC IWC AVSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.17	Insider Own	12.93%	Shs Outstand	109.71M	Perf Week	-4.40%
Market Cap	286.35M	Forward P/E	-	EPS next Y	-1.45	Insider Trans	-0.27%	Shs Float	95.53M	Perf Month	3.57%
Enterprise Value	50.96M	PEG	-	EPS next Q	-0.37	Inst Own	87.98%	Short Float	10.52%	Perf Quarter	89.13%
Income	-167.38M	P/S	-	EPS this Y	-45.07%	Inst Trans	-5.70%	Short Ratio	6.17	Perf Half Y	-46.07%
Sales	0.00M	P/B	1.17	EPS next Y	1.20%	ROA	-55.14%	Short Interest	10.05M	Perf YTD	-49.12%
Book/sh	2.22	P/C	1.09	EPS next 5Y	2.82%	ROE	-66.13%	52W High	7.85 -66.75%	Perf Year	-48.21%
Cash/sh	2.40	P/FCF	-	EPS past 3/5Y	33.38% -0.09%	ROIC	-62.11%	52W Low	1.28 103.11%	Perf 3Y	-34.26%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	18.25% 10.81%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	19.76%	Oper. Margin	-	ATR (14)	0.27	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.99	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	54.29	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.99	EPS Q/Q	-78.85%	SMA20	2.68%	Beta	1.30	Target Price	11.60
Payout	-	Debt/Eq	0.12	Sales Q/Q	-	SMA50	15.26%	Rel Volume	0.84	Prev Close	2.58
Employees	100	LT Debt/Eq	0.11	Earnings	May 12 BMO	SMA200	-32.45%	Avg Volume	1.63M	Price	2.61
IPO	Jul 24, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-24.75% -	Trades		Volume	1,366,628	Change	1.16%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-01-24	Upgrade	JP Morgan	Neutral → Overweight	$11
Dec-21-23	Upgrade	BofA Securities	Neutral → Buy	$4 → $6
Oct-30-23	Initiated	Wells Fargo	Overweight	$11
May-26-23	Downgrade	BofA Securities	Buy → Neutral	$8 → $3
May-25-23	Downgrade	JP Morgan	Overweight → Neutral	$19 → $9
Sep-16-22	Initiated	Jefferies	Buy	$12
Sep-09-22	Initiated	BTIG Research	Buy	$15
Nov-30-21	Initiated	H.C. Wainwright	Buy	$40
Sep-23-21	Initiated	Cantor Fitzgerald	Overweight	$40
Jan-26-21	Initiated	Needham	Buy	$37
Aug-18-20	Initiated	JP Morgan	Overweight	$33
Aug-18-20	Initiated	Cowen	Outperform
Aug-18-20	Initiated	BofA Securities	Buy	$33

Show Previous Ratings

Jun-18-25 04:05PM	Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA) (GlobeNewswire)
May-29-25 04:05PM	Annexon Biosciences to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +7.39% -6.42%
May-19-25 04:05PM	Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting (GlobeNewswire)
04:05PM	Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barre Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting (GlobeNewswire)
May-16-25 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.05%
08:00AM	Loading…
May-12-25 08:00AM	Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) +10.62%
May-09-25 05:00PM	Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting (GlobeNewswire) -5.88%
05:00PM	Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barre Syndrome (GBS) at the 2025 PNS Meeting (GlobeNewswire)
May-07-25 08:00AM	Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress (GlobeNewswire)
Apr-16-25 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.14%
Apr-15-25 07:12AM	Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck (Seeking Alpha)
Apr-10-25 09:24AM	Why Annexon Inc. (ANNX) Went Down On Thursday? (Insider Monkey)
Apr-09-25 03:20PM	Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder (Benzinga) -7.79%
Apr-08-25 04:05PM	Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barre Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire) -5.52%
04:05PM	Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barr Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire)
06:18PM	Loading…
Apr-03-25 06:18PM	Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barre Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire) -6.63% -7.65%
06:18PM	Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barr Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire)
Mar-17-25 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.77% -9.09%
Mar-16-25 06:05AM	Wells Fargo Predicts Up to ~440% Rally for These 2 Strong Buy Stocks (TipRanks)
Mar-03-25 08:00AM	Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) -9.47%
Feb-26-25 04:05PM	Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -12.05%
Feb-13-25 08:30AM	Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting (GlobeNewswire)
Jan-13-25 08:00AM	Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year (GlobeNewswire)
Jan-10-25 08:00AM	Annexon Expands Board of Directors with Appointment of Commercial Executive William BJ Jones (GlobeNewswire)
Jan-07-25 08:00AM	Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.96%
07:30AM	Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barr Syndrome (GBS) (GlobeNewswire)
Dec-05-24 08:00AM	Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting (GlobeNewswire)
Nov-19-24 03:00AM	The Dodgers World Series run brought attention to a rare disease. Annexon is stepping up to the plate. (Pharma Voice)
04:59PM	Loading…
Nov-15-24 04:59PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.78%
Nov-14-24 08:00AM	Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones (GlobeNewswire)
Nov-13-24 04:05PM	Annexon Biosciences to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-21-24 08:00PM	Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting (GlobeNewswire)
Oct-16-24 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-15-24 08:00AM	Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting (GlobeNewswire)
Sep-16-24 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-09-24 08:00AM	Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress (GlobeNewswire) +8.17%
Sep-03-24 08:00AM	Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio (GlobeNewswire) -5.09%
Aug-29-24 08:00AM	Annexon Biosciences to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-24 08:00AM	Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones (GlobeNewswire)
Aug-05-24 08:00AM	Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy (GlobeNewswire) -9.38%
Jul-16-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.02%
Jul-11-24 06:09PM	Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting (GlobeNewswire) +8.53% +11.15%
Jun-29-24 08:48PM	Are Analysts Bullish on Annexon, Inc. (ANNX) Right Now? (Insider Monkey)
Jun-28-24 09:40AM	Are Medical Stocks Lagging Annexon (ANNX) This Year? (Zacks)
Jun-27-24 09:55AM	Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Jun-25-24 05:00PM	Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barre Syndrome at the 2024 PNS Annual Meeting (GlobeNewswire)
05:00PM	Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barr Syndrome at the 2024 PNS Annual Meeting (GlobeNewswire)
Jun-24-24 06:35AM	7 Top Stocks Under $10: June 2024 Edition (InvestorPlace)
Jun-18-24 08:00AM	Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barr Syndrome At 2024 PNS Annual Meeting (GlobeNewswire) -5.41%
Jun-17-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-07-24 09:40AM	Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-05-24 11:04PM	Annexon Announces Pricing of $125 Million Underwritten Public Offering (GlobeNewswire) +13.36% -13.25%
10:57AM	Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals (Zacks)
09:55AM	Wall Street Analysts Think Annexon (ANNX) Could Surge 133.72%: Read This Before Placing a Bet (Zacks)
04:45AM	Annexons ANX005 offers improvement in Phase III GBS trial (Clinical Trials Arena)
Jun-04-24 05:06PM	Annexon Announces Proposed Public Offering of Common Stock (GlobeNewswire) +30.79%
12:06PM	Mid-Cap Firm Annexon's Nerve Disorder Candidate Shows Promise In Pivotal Late-Stage Study (Benzinga)
08:46AM	Annexon shares leap as Guillain-Barr drug reduces disability in phase 3 (FierceBiotech.com)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barre Syndrome (GlobeNewswire)
07:00AM	Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barr Syndrome (GlobeNewswire)
Jun-03-24 04:30PM	Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data (GlobeNewswire) -5.18%
May-20-24 09:35AM	Annexon (ANNX) Loses -5.04% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +8.08%
May-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-13-24 02:53PM	ANNX Stock Earnings: Annexon Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones (GlobeNewswire)
May-09-24 08:00AM	Annexon Biosciences to Present at the Bank of America Health Care Conference (GlobeNewswire)
May-07-24 12:30PM	Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting (GlobeNewswire)
May-01-24 10:15AM	Annexon (ANNX) to Report Q1 Earnings: What's in the Cards? (Zacks)
08:00AM	Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting (GlobeNewswire)
Apr-25-24 09:35AM	Down -43.02% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon (ANNX) (Zacks)
Apr-17-24 09:40AM	Are Medical Stocks Lagging Annexon (ANNX) This Year? (Zacks) -10.36%
Apr-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.89%
09:00AM	Turnstone Biologics Appoints William Waddill to its Board of Directors (GlobeNewswire)
Apr-14-24 12:52PM	10 Buy-Rated Stocks with Latest Insider Purchases (Insider Monkey)
Apr-10-24 06:15PM	Annexon, Inc. (ANNX) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Apr-03-24 08:00AM	Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-24 12:00PM	What Makes Annexon (ANNX) a New Buy Stock (Zacks) -7.53%
09:55AM	Wall Street Analysts Believe Annexon (ANNX) Could Rally 101.12%: Here's is How to Trade (Zacks)
Mar-28-24 05:31AM	Annexon Inc (ANNX) Reports Year-End Financials, Aligns with Analyst Projections (GuruFocus.com) -8.19%
Mar-26-24 08:53PM	ANNX Stock Earnings: Annexon Beats EPS for Q4 2023 (InvestorPlace) +13.52%
04:05PM	Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones (GlobeNewswire)
Mar-18-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.98%
Mar-14-24 08:40AM	Why Annexon (ANNX) Might Surprise This Earnings Season (Zacks)
Mar-12-24 02:51PM	J.P. Morgan Predicts up to 140% Rally for These 2 Strong Buy Stocks (TipRanks)
Feb-27-24 08:00AM	Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-21-24 08:00AM	Annexon to Host Virtual R&D Day on Guillain-Barr Syndrome, Focusing on its Serious Unmet Need and Annexon's Novel Therapeutic Approach (GlobeNewswire) -5.39%
Feb-20-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-13-24 01:10PM	Steven Cohen's Point72 Asset Management Acquires New Stake in Annexon Inc (GuruFocus.com) -7.73%
Jan-18-24 09:40AM	Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year? (Zacks) -5.87%
Jan-17-24 11:06AM	Annexon (ANNX) Stock Rallies 156% in 3 Months: Here's How (Zacks)
Jan-07-24 08:00PM	Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases (GlobeNewswire)
Dec-27-23 06:30AM	Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-23 05:27PM	Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) +29.51%
05:10PM	Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint (GlobeNewswire)
05:08PM	Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway (GlobeNewswire)
Dec-18-23 04:01PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Yednock Ted	Officer	Jul 14 '25	Proposed Sale	2.58	1,116	2,881		Jul 14 03:51 PM
Overdorf Michael	Officer	Jul 14 '25	Proposed Sale	2.61	853	2,226		Jul 14 03:26 PM
Lew Jennifer	Officer	Jul 14 '25	Proposed Sale	2.58	1,117	2,881		Jul 14 03:17 PM
Carson William H.	Director	Jun 30 '25	Buy	2.46	4,115	10,123	29,715	Jul 01 04:55 PM
Dananberg Jamie	CHIEF MEDICAL OFFICER	Feb 18 '25	Sale	2.96	5,521	16,342	33,479	Feb 20 04:54 PM
ARTIS DEAN RICHARD	EVP & CHIEF SCIENTIFIC OFFICER	Feb 18 '25	Sale	2.97	5,515	16,380	83,814	Feb 20 04:52 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Feb 18 '25	Sale	2.91	8,345	24,284	61,237	Feb 20 04:51 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Feb 18 '25	Sale	2.95	6,618	19,523	86,579	Feb 20 04:49 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Feb 18 '25	Sale	2.92	6,912	20,183	77,770	Feb 20 04:48 PM
Love Douglas	PRESIDENT AND CEO	Feb 13 '25	Sale	2.95	5,021	14,812	351,554	Feb 18 04:30 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Feb 13 '25	Sale	2.98	1,786	5,322	84,682	Feb 18 04:30 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Feb 13 '25	Sale	2.99	1,425	4,261	93,197	Feb 18 04:30 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Feb 13 '25	Sale	2.99	1,783	5,331	69,582	Feb 18 04:30 PM
Yednock Ted	Officer	Feb 18 '25	Proposed Sale	2.91	8,345	24,321		Feb 18 03:21 PM
Lew Jennifer	Officer	Feb 18 '25	Proposed Sale	2.92	8,338	24,319		Feb 18 03:15 PM
ARTIS DEAN RICHARD	Officer	Feb 18 '25	Proposed Sale	2.97	5,515	16,359		Feb 18 03:15 PM
Dananberg Jamie	Officer	Feb 18 '25	Proposed Sale	2.96	5,521	16,359		Feb 18 03:13 PM
Overdorf Michael	Officer	Feb 18 '25	Proposed Sale	2.95	6,618	19,514		Feb 18 03:11 PM
Yednock Ted	Officer	Feb 13 '25	Proposed Sale	2.98	1,783	5,316		Feb 13 03:18 PM
Love Douglas	Officer	Feb 13 '25	Proposed Sale	2.95	5,021	14,799		Feb 13 03:13 PM
Lew Jennifer	Officer	Feb 13 '25	Proposed Sale	2.98	1,786	5,314		Feb 13 03:12 PM
Overdorf Michael	Officer	Feb 13 '25	Proposed Sale	2.99	1,425	4,265		Feb 13 03:06 PM
Love Douglas	PRESIDENT AND CEO	Jan 06 '25	Option Exercise	1.41	37,994	53,556	356,575	Jan 08 05:58 PM
Carson William H.	Director	Dec 02 '24	Buy	5.33	3,200	17,056	25,600	Dec 04 06:12 PM
Love Douglas	PRESIDENT AND CEO	Oct 30 '24	Option Exercise	1.85	114,449	211,742	310,570	Nov 01 04:15 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Oct 15 '24	Option Exercise	1.85	5,408	10,005	76,773	Oct 17 05:09 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Oct 15 '24	Sale	7.41	5,408	40,073	71,365	Oct 17 05:09 PM
Yednock Ted	Officer	Oct 15 '24	Proposed Sale	7.41	5,408	40,073		Oct 15 02:03 PM
Carson William H.	Director	Oct 01 '24	Buy	5.97	3,200	19,104	22,400	Oct 02 04:15 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Sep 19 '24	Sale	7.10	4,500	31,950	0	Sep 20 04:30 PM
Yednock Ted	Officer	Sep 19 '24	Proposed Sale	7.10	4,500	31,950		Sep 19 12:32 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Sep 12 '24	Sale	6.16	5,500	33,880	4,500	Sep 16 04:30 PM
Yednock Ted	Officer	Sep 12 '24	Proposed Sale	6.16	5,500	33,880		Sep 12 10:24 AM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Sep 05 '24	Sale	5.64	5,500	31,020	10,000	Sep 06 04:30 PM
Yednock Ted	Officer	Sep 05 '24	Proposed Sale	5.64	5,500	31,020		Sep 05 10:15 AM
Carson William H.	Director	Sep 03 '24	Buy	5.48	3,200	17,536	19,200	Sep 04 04:34 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Aug 29 '24	Sale	5.95	5,500	32,725	15,500	Aug 30 06:00 PM
Yednock Ted	Officer	Aug 29 '24	Proposed Sale	5.95	5,500	32,725		Aug 29 02:08 PM
Carson William H.	Director	Aug 01 '24	Buy	6.24	3,200	19,968	16,000	Aug 05 07:53 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANNX

Annexon Inc

Upgrade your FINVIZ experience